CRISPR Therapeutics (CRSP) is back in focus after new Phase 1a durability data for CTX310, its in vivo ANGPTL3 gene editing therapy, highlighted sustained lipid reductions one year after a single infusion.
At a share price of $56.92, CRISPR Therapeutics has had a mixed year, with a 30 day share price return of 14.83% and a year to date share price return of 5.86%, while the 1 year total shareholder return of 7.44% suggests that momentum has been improving recently as investors react to the CTX310 update and the recent earnings beat.
Spot similar gene editing and biotech breakouts by scanning our hand picked 20 high quality undiscovered gems that share characteristics with CRISPR Therapeutics' recent CTX310 update.CRISPR Therapeutics now has fresh clinical momentum and a history of sharp swings in shareholder returns. The next step is to consider whether the current US$56.92 share price reflects that reality or stretches it.
Price to Book of 3.2x: Is it justified for CRISPR Therapeutics?
On traditional valuation, CRISPR Therapeutics trades on a P/B multiple of 3.2x, which lines up with a company that is loss making yet priced for future progress.
The P/B ratio compares the market value of the equity to the accounting book value on the balance sheet. For a company like CRISPR Therapeutics that is still unprofitable and heavily focused on research and development, investors often lean on P/B because earnings are negative and do not yet reflect the potential of the underlying pipeline.
According to Simply Wall St, CRISPR Therapeutics is described as good value on a P/B basis when stacked against its peer average of 12.6x. This points to a materially lower valuation multiple than many direct comparables. However, compared with the broader US Biotechs industry average P/B of 2.5x, the stock screens as more expensive. This suggests the market is assigning a premium relative to the wider group even though it trades at a discount to a tighter peer set.
Investors comparing these benchmarks are effectively weighing whether the lower multiple versus close peers or the premium versus the wider industry better captures the long term prospects of CRISPR Therapeutics. The final judgment rests on how much confidence they place in the company converting its pipeline into sustainable returns on equity over time.
Result: Price to book ratio of 3.2x (ABOUT RIGHT)
See what the numbers say about this price in the fuller breakdown in See what the numbers say about this price — find out in our valuation breakdown.
However, CRISPR Therapeutics still faces key risks, including ongoing net losses of US$451.139m and clinical or regulatory setbacks that could cool enthusiasm around CTX310 and the wider pipeline.
Find out about the key risks to this CRISPR Therapeutics narrative.
Another view on CRISPR Therapeutics using our DCF model
The earlier P/B check suggested the current $56.92 share price for CRISPR Therapeutics is roughly in line with what book value might justify. Our DCF model points in a very different direction. Simply Wall St estimates future cash flows could support a fair value closer to $223.21, which implies the stock is trading about 74.5% below that level. As an investor, which signal feels more grounded to you, the balance sheet or the cash flow outlook?
For a closer look at how this cash flow view is built and where the key assumptions sit, take a moment to review Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CRISPR Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 54 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Given the mixed signals around CRISPR Therapeutics, it can be helpful to understand what is driving the more optimistic perspectives for yourself and not wait too long to form an opinion. Start by checking the 2 key rewards.
Looking for more investment ideas beyond CRISPR Therapeutics?
If CRISPR Therapeutics has caught your attention, do not stop here. Broaden your watchlist now so you have more options when the next opportunity appears.
- Target resilient opportunities that aim to limit downside risk by reviewing our 73 resilient stocks with low risk scores.
- Hunt for established companies that combine quality with attractive pricing through the 54 high quality undervalued stocks.
- Prioritise financial strength and staying power by checking the list of solid balance sheet and fundamentals (52 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com